CME

CME


HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

February 05, 2024

Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted ther